JP2021119189A5 - - Google Patents

Download PDF

Info

Publication number
JP2021119189A5
JP2021119189A5 JP2021078788A JP2021078788A JP2021119189A5 JP 2021119189 A5 JP2021119189 A5 JP 2021119189A5 JP 2021078788 A JP2021078788 A JP 2021078788A JP 2021078788 A JP2021078788 A JP 2021078788A JP 2021119189 A5 JP2021119189 A5 JP 2021119189A5
Authority
JP
Japan
Prior art keywords
dystonia
use according
subject
predopidine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021078788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021119189A (ja
JP7278327B2 (ja
Filing date
Publication date
Priority claimed from JP2019531546A external-priority patent/JP7278210B2/ja
Application filed filed Critical
Publication of JP2021119189A publication Critical patent/JP2021119189A/ja
Publication of JP2021119189A5 publication Critical patent/JP2021119189A5/ja
Application granted granted Critical
Publication of JP7278327B2 publication Critical patent/JP7278327B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021078788A 2016-08-24 2021-05-06 ジストニアを治療するためのプリドピジンの使用 Active JP7278327B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US62/379,175 2016-08-24
US201662395319P 2016-09-15 2016-09-15
US62/395,319 2016-09-15
JP2019531546A JP7278210B2 (ja) 2016-08-24 2017-08-24 ジストニアを治療するためのプリドピジンの使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019531546A Division JP7278210B2 (ja) 2016-08-24 2017-08-24 ジストニアを治療するためのプリドピジンの使用

Publications (3)

Publication Number Publication Date
JP2021119189A JP2021119189A (ja) 2021-08-12
JP2021119189A5 true JP2021119189A5 (cg-RX-API-DMAC7.html) 2022-03-22
JP7278327B2 JP7278327B2 (ja) 2023-05-19

Family

ID=61246309

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531546A Active JP7278210B2 (ja) 2016-08-24 2017-08-24 ジストニアを治療するためのプリドピジンの使用
JP2021078788A Active JP7278327B2 (ja) 2016-08-24 2021-05-06 ジストニアを治療するためのプリドピジンの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019531546A Active JP7278210B2 (ja) 2016-08-24 2017-08-24 ジストニアを治療するためのプリドピジンの使用

Country Status (12)

Country Link
US (2) US11826361B2 (cg-RX-API-DMAC7.html)
EP (1) EP3503890B1 (cg-RX-API-DMAC7.html)
JP (2) JP7278210B2 (cg-RX-API-DMAC7.html)
CN (1) CN110012661A (cg-RX-API-DMAC7.html)
AU (1) AU2017315781B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019003731A2 (cg-RX-API-DMAC7.html)
CA (1) CA3035099C (cg-RX-API-DMAC7.html)
DK (1) DK3503890T3 (cg-RX-API-DMAC7.html)
ES (1) ES3009437T3 (cg-RX-API-DMAC7.html)
MX (1) MX2019002190A (cg-RX-API-DMAC7.html)
PL (1) PL3503890T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018039475A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
JP7603713B2 (ja) * 2020-05-04 2024-12-20 プリレニア ニューロセラピューティクス リミテッド 選択的s1rアゴニストを使用するウイルス感染、疾患、又は障害の治療
CN116472043A (zh) 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
KR20250121149A (ko) * 2022-12-27 2025-08-11 프리레니아 뉴로테라퓨틱스 엘티디. 소아 헌팅턴병 치료를 위한 프리도피딘
WO2024258929A1 (en) * 2023-06-12 2024-12-19 Unravel Biosciences, Inc. Methods for treating diseases associated with taf1 loss of function
WO2025188979A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds and pridopidine for treatment of huntington's disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
CA2569843A1 (en) * 2004-06-08 2005-12-22 A. Carlsson Research Ab New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
MX2009011020A (es) 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
US8562488B2 (en) * 2009-10-05 2013-10-22 The Cleveland Clinic Foundation Systems and methods for improving motor function with assisted exercise
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) * 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
US20140037850A1 (en) * 2012-08-06 2014-02-06 General Electric Company Corrosion and wear resistant organic coatings
CA2913781C (en) * 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
ES2972205T3 (es) 2017-01-20 2024-06-11 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento del síndrome x frágil
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias

Similar Documents

Publication Publication Date Title
US8512751B2 (en) Pharmaceutical compositions for sleep disorders
US9028868B2 (en) Methods and compositions for treatment of attention deficit disorder
JP2023519965A5 (cg-RX-API-DMAC7.html)
TWI302460B (en) Pharmaceutical compositions and use thereof
JP2019503365A5 (cg-RX-API-DMAC7.html)
JP2010512413A5 (cg-RX-API-DMAC7.html)
US10617651B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US9511032B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
FI3982963T3 (fi) Koostumus, johon sisältyy pridopidiini ja sen analogi, huntingtonin taudin ja sen oireitten hoitoa varten
JP2019524897A5 (cg-RX-API-DMAC7.html)
US9034902B2 (en) Methods for treatment of attention deficit hyperactivity disorder
US20150125521A1 (en) Compositions for treatment of attention deficit hyperactivity disorder
US20180064669A1 (en) Compositions and methods of providing thyroid hormone or analogs thereof
US20240075035A1 (en) Methods and compositions for treating sleep apnea
JPS61286326A (ja) パ−キンソン病治療薬
US11241391B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
JP2021073275A (ja) 甲状腺ホルモン又はそのアナログを提供する組成物及び方法
BRPI0609779A2 (pt) composição farmacêutica oral de liberação controlada, e, método de tratamento da deficiência de hormÈnio da tireóide
WO2023112024A1 (en) Method of treating parkinson's disease
JP2008535907A5 (cg-RX-API-DMAC7.html)
JP2009501205A (ja) 精神病治療用組成物
CN103622997A (zh) 包含谷氨酸受体阻断剂盐酸美金刚或其药学可接受的盐与β受体阻断剂的药物组合物
Perkins et al. Pharmacotherapy Options in Restless Legs Syndrome
HK40004871A (en) Compositions and methods of providing thyroid hormone or analogs thereof
EP3452077A1 (en) Compositions and methods of providing thyroid hormone or analogs thereof